Bleeding with Direct Oral Anticoagulants vs Warfarin: Clinical Experience

Abstract

The risk of bleeding in the setting of anticoagulant therapy continues to be re-evaluated following the introduction of a new generation of direct oral anticoagulants (DOACs). Interruption of DOAC therapy and supportive care may be sufficient for the management of patients who present with mild or moderate bleeding, but in those with life-threatening bleeding, a specific reversal agent is desirable. We review the phase 3 clinical studies of dabigatran, rivaroxaban, apixaban, and edoxaban in patients with nonvalvular atrial fibrillation, in the context of bleeding risk and management.

Keywords: Apixaban; Bleeding management; Clinical trials; Dabigatran; Direct oral anticoagulants; Edoxaban; Rivaroxaban.